• Publications
  • Influence
Hydrogels in Biology and Medicine: From Molecular Principles to Bionanotechnology†
Hydrophilic polymers are the center of research emphasis in nanotechnology because of their perceived “intelligence”. They can be used as thin films, scaffolds, or nanoparticles in a wide range of
A tough biodegradable elastomer
TLDR
A tough biodegradable elastomer is designed, synthesized, and characterized from biocompatible monomers that forms a covalently crosslinked, three-dimensional network of random coils with hydroxyl groups attached to its backbone.
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
TLDR
In vivo as well as ex vivo genome editing using adeno-associated virus, lentivirus, or particle-mediated delivery of guide RNA in neurons, immune cells, and endothelial cells is demonstrated, suggesting that Cas9 mice empower a wide range of biological and disease modeling applications.
Drug delivery and targeting.
When a pharmaceutical agent is encapsulated within, or attached to, a polymer or lipid, drug safety and efficacy can be greatly improved and new therapies are possible. This has provided the impetus
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
TLDR
The potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application is demonstrated and remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo are demonstrated.
Nanocarriers as an emerging platform for cancer therapy.
TLDR
The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Polymeric systems for controlled drug release.
TLDR
Kevin Shakesheff investigates new methods of engineering polymer surfaces and the application of these engineered materials in drug delivery and tissue engineering.
Microscale technologies for tissue engineering and biology.
TLDR
An overview of the use of microfluidics, surface patterning, and patterned cocultures in regulating various aspects of cellular microenvironment is discussed, as well as the application of these technologies in directing cell fate and elucidating the underlying biology.
Knocking down barriers: advances in siRNA delivery
TLDR
The authors would like to clarify that, following a Phase I/II trial in patients with wet age-related macular degeneration, the siRNA drug candidate PF-4523655 (RTP801i-14) is now being studied in a Phase II trial for diabetic macular oedema conducted by Pfizer in collaboration with Quark.
Knocking down barriers: advances in siRNA delivery
TLDR
An update on the progress of RNAi therapeutics is provided and novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids are highlighted.
...
1
2
3
4
5
...